Article information
Full text is only aviable in PDF
References
[1.]
B.W. Gunderson, G.H. Ross, K.H. Ibrahim, J.C. Rotschafer.
What do we really know about antibiotic pharmacodynamics?.
Pharmacotherapy, 21 (2001), pp. 302S-318S
[2.]
F. Scaglione.
Can PK/PD be used in everyday clinical practice.
Int J Antimicrob Agents, 19 (2002), pp. 349-353
[3.]
J.L. Kuti, C.H. Nightingale, D.P. Nicolau.
Optimizing pharmacodynamics target attainment using the MYSTIC antibiogram: data collected in North America in 2002.
Antimicrob Agents Chemother, 48 (2004), pp. 2464-2470
[4.]
C. Li, J.L. Kuti, C.H. Nightingale, D.P. Nicolau.
Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
J Clin Pharmacol, 46 (2006), pp. 171-178
[5.]
S. Sakka, A. Glauner, J. Bulitta, et al.
Population pharmacokinetics and pharmacodynamics of continuous versus short term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
Antimicrob Agents Chemother, 51 (2007), pp. 3304-3310
[6.]
V.H. Tam, P.S. McKinnon, R.L. Akins, G.L. Drusano, M.J. Rybak.
Pharmacokinetics and pharmacodynamics of cefepime in patients with various degreees of renal function.
Antimicrob Agents Chemother, 47 (2003), pp. 853-861
[7.]
G.L. Drusano.
Antimicrobial pharmacodynamics: critical interactions of “bug and drug”.
Nat Rev Microbiol, 2 (2004), pp. 289-300
[8.]
A.R. Marra, S.B. Wey, A. Castelo, et al.
Nosocomial bloodstream infections caused by Klebsiella pneumonia; impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence.
BMC Infect Dis, 6 (2006), pp. 24
[9.]
C.I. Kang, S.H. Kim, W.B. Park, et al.
Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumonia: risk factors for mortality and treatment outcome with special emphasis on antimicrobial therapy.
Antimicrob Agents Chemother, 48 (2004), pp. 4574-4581
[10.]
J.F. Mohr, A. Wanger, J.H. Rex.
Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial Gram-negative infections in critically ill patients.
Diagnostic Microbiol Infect Dis, 48 (2004), pp. 125-130
Copyright © 2012. Elsevier Editora Ltda.. All rights reserved
